EW News and Press, Edwards Lifesciences Corporation From 07/28/22

Edwards Lifesciences Corporation (EW) Q2 2022 Earnings Conference Call July 28, 2022, 05:00 PM ET Company Participants Mark Wilterding - VP, IR and Treasurer Mike Mussallem - Chairman and CEO Scott Ullem - CFO Larry Wood - Global Leader, TAVR Bernard Zovi...

Shares of Edwards Lifesciences ( NYSE: EW ) lost 5.9% to $101 after hours, as the heart-focused medical device maker reported Q2 earnings that missed expectations and cut its FY 2022 guidance. EW posted Q2 non-GAAP EPS of $0.63 which missed estimates by $0.01 ....

Edwards Lifesciences press release ( NYSE: EW ): Q2 Non-GAAP EPS of $0.63 misses by $0.01 . Revenue of $1.37B (-0.7% Y/Y) misses by $30M . Shares -7% . For total Edwards, the company now expects full year 2022 sales of $5.35 to $5.55 billion. ($5.71B CO...

EDWARDS LIFESCIENCES REPORTS SECOND QUARTER RESULTS PR Newswire IRVINE, Calif. , July 28, 2022 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2022. Second Quarter Hi...

We believe the healthcare sector's strong growth momentum with average revenue growth of 3.8% QoQ indicates a positive outlook, with the equipment industry forecasted at a market CAGR of 5.5%. For the healthcare equipment industry, we believe the outlook is supported by the average gu...

Edwards Lifesciences ( NYSE: EW ) is scheduled to announce Q2 earnings results on Thursday, July 28th, after market close. The consensus EPS Estimate is $0.64 (flat Y/Y) and the consensus Revenue Estimate is $1.4B (+1.4% Y/Y). Over the last 2 years, EW has beaten EPS...

EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON JULY 28, 2022 PR Newswire IRVINE, Calif. , July 21, 2022 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2022 after the mar...

Although the healthcare sector has largely resisted this year's downward pressure, it is likely to succumb as pressure increases. Healthcare stocks have a well-deserved reputation for cyclical defense, but they are more likely to underperform in "secular" bear markets. Healthcare ...

Bridgewater Associates' 13F portfolio value increased ~45% from ~$17.20B to ~$24.81B this quarter. They more than doubled their stakes in emerging market ETFs this quarter. The top three individual stock positions are Procter & Gamble, Alibaba Group Holding, and Johnson & ...

Wedgewood Partners’ 13F portfolio value decreased from ~$753M to $709M this quarter. They increased Meta Platforms, Taiwan Semi, and PayPal while reducing Alphabet and Keysight Technologies. Their top five positions are at 38% of the overall portfolio. For further det...